*June 2020*

Note: Capmatinib was approved by the FDA in May 2020 for MET exon 14 skipping mutation.

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved capmatinib (Tabrecta; formerly INC280) for patients with MET exon 14 skipping (METex14) mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer (NSCLC), according to Novartis, the drug developer.1

“With the remarkable overall response rates seen both in treatment-naïve and previously treated patients, we are thrilled that MHLW had added [capmatinib] as a new treatment option for patients with advanced NSCLC with METex14,” Brian Gladsden, president of Novartis Oncology Japan, said in a press release. “Today’s approval reinforces the potential benefit this new MET inhibitor can bring to thousands of patients diagnosed in Japan each year and is a positive step in our journey to transform the lives of patients with lung cancer.” Read more.